March 27 (Reuters) - Equillium Inc EQ.O:
EQUILLIUM ANNOUNCES RESULTS OF THE PHASE 3 EQUATOR STUDY OF ITOLIZUMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE
EQUILLIUM INC - ITOLIZUMAB DID NOT IMPROVE RESPONSE RATES AT DAY 29
EQUILLIUM INC - ITOLIZUMAB ACHIEVED STATISTICAL SIGNIFICANCE IN LONGER-TERM OUTCOMES
EQUILLIUM INC - BREAKTHROUGH THERAPY DESIGNATION REQUEST SUBMITTED TO FDA, FEEDBACK EXPECTED DURING MAY 2025
Source text: ID:nBw7QkrD2a
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.